Experimental antibody takes aim at eye inflammation
NCT ID NCT07218770
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called REGN7041 in 72 people with active noninfectious uveitis, a condition causing inflammation inside the eye. The drug is an antibody designed to calm the immune system. Since this is the first time it's tested in humans, the main goal is to check safety and side effects. Researchers will also measure drug levels in blood and eye fluid, and see if the body makes antibodies against the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN7041 (an experimental antibody that targets immune cells)
- What this could lead to
- If successful, this could point toward a new treatment option for people with active noninfectious uveitis, potentially reducing eye inflammation without infection risk.
- What could go wrong
- This is a first-in-human study, so safety and effectiveness are unknown. The drug may cause side effects or not work as hoped. Results are early and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE NONINFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Illinois Retina Associates
Oak Park, Illinois, 60304, United States
-
Retina Consultants of Texas
Katy, Texas, 77494, United States
-
Retina Consultants of Texas - Houston
Bellaire, Texas, 77401, United States
-
Retinal Consultants - Sacramento
Sacramento, California, 95825, United States
-
Tennessee Retina
Nashville, Tennessee, 37203, United States